APA Zitierstil

Chen, Y., Li, F., Li, D., Liu, W., & Zhang, L. (2021). Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway. Clinical immunology (Orlando, Fla.), 227, 108728. https://doi.org/10.1016/j.clim.2021.108728

Chicago Zitierstil

Chen, Ying, Fangxuan Li, Dan Li, Wenxin Liu, und Lei Zhang. "Atezolizumab and Blockade of LncRNA PVT1 Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via JAK2/STAT3/PD-L1 Pathway." Clinical Immunology (Orlando, Fla.) 227 (2021): 108728. https://dx.doi.org/10.1016/j.clim.2021.108728.

MLA Zitierstil

Chen, Ying, et al. "Atezolizumab and Blockade of LncRNA PVT1 Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via JAK2/STAT3/PD-L1 Pathway." Clinical Immunology (Orlando, Fla.), vol. 227, 2021, p. 108728.